BRIEF

on ZetrOZ Systems

New Study Finds ZetrOZ Systems’ Acoustic Medicine Technology Effective for Chronic Low Back Pain

A recent study reveals that low-intensity continuous ultrasound, as deployed by ZetrOZ Systems' sustained acoustic medicine (sam®) technology, reduces chronic low back pain and the need for pain medication.

The study was presented at the 2024 Annual Meeting of the American College of Sports Medicine. It involved a randomized, double-blind, placebo-controlled trial examining 65 participants with chronic low back pain.

The LICUS-treated group showed significant improvement, reducing pain levels and medication use over eight weeks compared to the placebo group. This treatment proved to be a safe and non-invasive option.

ZetrOZ Systems' CEO, Dr. George K. Lewis, expressed satisfaction with the findings, confirming the effectiveness of the sam® technology in treating various soft tissue injuries and chronic conditions.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all ZetrOZ Systems news